Last Price
1.90
Today's Change
+0.52 (37.68%)
Day's Change
1.73 - 2.64
Trading Volume
103,496,597
Market Cap
6 Million
Shares Outstanding
33 Million
Avg Volume
99,806
Avg Price (50 Days)
3.23
Avg Price (200 Days)
3.67
PE Ratio
-0.30
EPS
-6.36
Earnings Announcement
20-Feb-2025
Previous Close
1.38
Open
2.17
Day's Range
1.73 - 2.64
Year Range
1.32 - 15.8
Trading Volume
103,496,597
1 Day Change
37.68%
5 Day Change
31.94%
1 Month Change
-38.71%
3 Month Change
-66.55%
6 Month Change
-49.60%
Ytd Change
8.57%
1 Year Change
-36.03%
3 Year Change
-97.16%
5 Year Change
-95.41%
10 Year Change
-98.07%
Max Change
-99.64%
No result.
Sector: Healthcare - Healthcare
Industry: Biotechnology
Description:
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various forms of cancer. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.